Thromb Haemost 1998; 80(02): 351
DOI: 10.1055/s-0037-1615208
Letters to the Editor
Schattauer GmbH

Human Parvovirus B19 Infection in Persons with Haemophilia

C. Prowse
1   SNBTS National Science Laboratory, Edinburgh
,
B. Dow
2   SNBTS Microbiology Reference Unit
,
S. J. Pelly
3   SNBTS Product Services Department
,
E. McIntosh
3   SNBTS Product Services Department
,
S. Reading
3   SNBTS Product Services Department
,
G. D. O. Lowe
4   Department of Medicine, Royal Infirmary, Glasgow
,
B. Gibson
5   Royal Hospital for Sick Children, Glasgow
,
P. Cachia
6   Ninewells Hospital, Dundee
,
A. Thomas
7   Royal Hospital for Sick Children, Edinburgh and Royal Infirmary, Edinburgh, UK
,
R. Dennis
8   Royal Infirmary, Edinburgh, UK
,
C. A. Ludlam
8   Royal Infirmary, Edinburgh, UK
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 10. Februar 1998

Accepted 09. April 1998

Publikationsdatum:
08. Dezember 2017 (online)

 

 
  • References

  • 1 Aygören-Pürsün E, Scharrer I. German Kogenate Study Group.. A multicentre pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant Factor VIII in the treatment of patients with haemophilia A.. Thromb Haemost 1998; 78: 1352-6.
  • 2 Prowse CV. Parvovirus B19 and blood products.. Lancet 1994; 343: 1101.
  • 3 Prowse CV, Ludlam CA, Yap PL. Human parvovirus B19 and blood products.. Vox Sang, 1998; 72: 1-10.
  • 4 Prowse CV, Dow B, Pelly J. et al. Studies on B19 parvovirus in the normal and haemophilic. Scottish population in 1995.. Thromb Haemost 1998; Suppl: 455 (PS-1857).
  • 5 Williams MD, Cohen BJ, Beddall AC, Pasi RJ, Mortimer P, Hill FGW. Transmission of human parvovirus B19 by coagulation factor concentrates.. Vox Sang 1990; 58: 177-81.